磷酸二酯酶5在心力衰竭中作用的研究进展  

Research progress of phosphodiesterase 5 in heart failure

作　　者：杨洋[1] 张雅茸 杨红琴 王婧[1] 赵红梅 YANG Yang;ZHANG Yarong;YANG Hongqin;WANG Jing;ZHAO Hongmei(Department of Pathophysiology,Institute of Basic Medical Sciences CAMS,School of Basic Medicine PUMC,Beijing 100005,China)

机构地区：[1]中国医学科学院基础医学研究所、北京协和医学院基础学院病理生理学系,北京100005

出　　处：《基础医学与临床》2024年第5期724-728,共5页Basic and Clinical Medicine

基　　金：国家自然科学基金(82270403);国家重点研发计划(2019YFA0801804,2019YFA081703)。

摘　　要：磷酸二酯酶5(PDE5)是环磷酸鸟苷(cGMP)特异性水解酶,是由一氧化氮(NO)激活的可溶性鸟苷酸环化酶(sGC)靶向cGMP产生的。PDE5催化cGMP中磷酸二酯键的水解,从而将cGMP转化为无活性的5′-GMP形式,cGMP-PKG轴功能障碍将引起心脏重塑,是心力衰竭(HF)的主要原因之一。但PDE5抑制剂治疗心力衰竭的临床疗效存在争议。本文总结了近年来PDE5在心力衰竭中的作用机制和研究进展,对未来临床应用PDE5靶向治疗心力衰竭具有重要的指导意义。Phosphodiesterase 5(PDE5),a cyclic guanosine monophosphate(cGMP)-specific hydrolase,is targets cGMP produced by soluble guanosine cyclase(sGC)that is activated by nitric oxide(NO).It catalyzes the hydrolysis of the phosphodiester bond in cGMP and converts cGMP to the inactive 5′-GMP form.The cGMP-PKG axis dysfunction is one of the main causes of heart failure(HF)and causes cardiac remodeling.However,the clinical efficacy of PDE5 inhibitors in the treatment of heart failure is controversial.This paper summarizes the mechanism and research progress of PDE5 in heart failure in recent years,which has important significance for the clinical application of PDE5 in heart failure.

关 键 词：心力衰竭 磷酸二酯酶5 磷酸二酯酶抑制剂 环磷酸鸟苷 

分 类 号：R363[医药卫生—病理学]